magicmedindustries.com1

C o r p o r a t e P r e s e n t a t i o n

S e p t e m b e r 2 0 2 0

magicmedindustries.com2

This presentation contains certain statements that may be deemed "forward-looking statements". All

statements in this document, other than statements of historical fact, that address events or

developments that MagicMed Industries (“the Company”) expects to occur, are forward looking

statements. Forward looking statements are statements that are not historical facts and are generally,

but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends",

"estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would",

"may", "could" or "should" occur.

Although the Company believes the expectations expressed in such forward-looking statements are

based on reasonable assumptions, such statements are not guarantees of future performance and

actual results may differ materially from those in the forward- looking statements. Factors that could

cause the actual results to differ materially from those in forward looking statements include, failure to

successfully negotiate or subsequently close such transactions, inability to obtain required shareholder

or regulatory approvals, uncertainty with respect to findings under general economic, market or

business conditions. Investors are cautioned that any such statements are not guarantees of future

performance and actual results or developments may differ materially from those projected in the

forward-looking statements. Forward looking statements are based on the beliefs, estimates and

opinions of the Company's management on the date the statements are made. The Company

undertakes no obligation to update these forward-looking statements in the event that management's

beliefs, estimates or opinions, or other factors, should change, other than as required under applicable

securities laws.

Forward Looking Statements

magicmedindustries.com3

MagicMed Industries intends to partner with pharmaceutical and

other companies to develop psychedelic-derived medicinal and

licit consumer goods products.

MagicMed’s molecular derivatives library, the Psybrary™ is

anticipated to be an essential building block from which industry

can develop new patented products.

The initial focus of the Psybrary™ is on psilocybin, which is

expected to be opportunistically expanded to other psychedelics

like MDMA, ketamine, ibogaine, mescaline, and ayahuasca.

About MagicMed

magicmedindustries.com4

Investment Highlights

Experienced Leadership: Proven team has previously developed and

partnered opiate and cannabinoid programs with significant

corporate partners.

Invested Team: Entire current management and science team well

invested in the company.

Leveraging Strength: Relationships with established pharmaceutical

/ consumer good manufacturers will be built upon.

Opportunistic: Deep science and business expertise enables rapid

Psybrary™ expansion to a broad range of psychedelic derivatives.

Short Term Milestones: New derivatives, patents and first partner

engagements all targeted for 2020.

Solid Business Model: Controlled cost structure with sustainable

near-term revenues via milestone-based compensation model.

Bluesky: Royalty sharing opens the door to participating in

potential long-term big pharma market revenues.

magicmedindustries.com5

Improved Products Needed To

Treat Psychological Indications

• Pharma is looking for more effective and safer products

to address numerous psychological indications that are

growing in need and that are currently poorly treated.

• Psychedelic agents have recently shown promise in this

area but are limited in market potential because they

require in-clinic administration and therapist oversight.

• In order to respond to increased needs and to create

broader market share, the pharma industry will require

scientifically engineered versions of natural psychedelic

molecules to improve on therapeutic benefit and to

reduce toxicities (side effects).

• Once developed and approved, new medicinal products

will be useful for both prescribed and in-clinic

administration to patients.

magicmedindustries.com6

Why Pharma Needs MagicMed

• Creation of new psychedelic-based medicinal

products requires innovative processes, technology

and expertise that pharma and consumer goods

companies do not possess internally.

• Numerous companies are aspiring to develop new

psychedelic-derived pharmaceutical, nutraceutical,

and consumer goods products.

• The MagicMed team has previously engaged with

large industrial partners to develop new derivatives

in other medicinal product markets, such as opiates

and cannabinoids.

• The MagicMed Psybrary™ and field expertise

provides the concrete head start necessary for

success in a competitive environment.

magicmedindustries.com7

• MagicMed scientists start with a natural psychedelic

molecule such as psilocybin and modify its structure to

create many new derivative molecules which will form

part of the MagicMed Psybrary™.

• The proprietary scientific tools MagicMed employs for

its derivatizations are trade secrets developed in-house

from our decades of research and development in the

field of natural product biochemistry.

• MagicMed partners will be able to search, select and test

from the derivatives in the Psybrary™ and use them as a

building block for their own product development based

on the indication that they are targeting (anxiety,

depression, addiction, PTSD and many others).

• The MagicMed team will then continue to work with its

partners to further define and improve upon their

selected derivative molecules to create finished

medicinal product candidates and, in future, licit

consumer products.

MagicMed Process

magicmedindustries.com8

Natural molecules such as psilocybin cannot be

patented as a molecular composition.

New molecular derivative compositions in the Psybrary™

are patentable as are MagicMed’s proprietary methods

of manufacturing the derivatives within the Psybrary™.

MagicMed plans to file numerous patents to stake

broad claims over the new derivative molecules

contained in the Psybrary™.

MagicMed’s partners will in turn potentially gain a

significant edge over their competitors in new product

development based on Psybrary™ molecules that are

fully patent protected.

Building Intellectual

Property Assets

magicmedindustries.com9

Source: clinicaltrials.gov

Major Underserved Pharmaceutical Markets

• Pharmaceutical market opportunities for psychedelic

derivatives, especially Psilocybin, are estimated in the

billions of dollars, with encouraging early clinical data

being generated for many indications.

• Moreover, consumer goods market applications are

anticipated to follow in future as licit consumer markets

open up through decriminalization.

• It is expected that future pharma partners and other

consumer goods companies will actively seek improved

psychedelic-derived molecules for product

development.

• The MagicMed Psybrary™ is designed to provide

partners with a significant head start in the

development of new medicinal and other products.

magicmedindustries.com10

• The numerous and distinct medicinal markets allow us to work with

multiple major industry partners:

▪ Diversified partners allow for a conservative, multiple base hit

strategy.

▪ Pharma partnerships will be the focus although we will add on

consumer goods partnerships in future as decriminalization

begins to open new licit consumer goods markets.

▪ Partners will pay fixed and variable costs plus milestone

payments enabling MagicMed to quickly reach positive cash

flow.

▪ Long-term product royalties offer the larger blue-sky

opportunities.

• While we are working with partners and maintaining positive

revenues, we will continue to expand the Psybrary™, a sought-after

industry asset that will grow in value over time.

Our Business Strategy

magicmedindustries.com11

Objective Timelines

• Lab, science team expansion

• University partnership

• Psybrary™ development

• Multiple patent filings

• Target: Onboard 1st partner

2020

• Ongoing Psybrary™ expansion

• Expansion of patent filings

• Target: Additional partners

• Target: Public listing Q1/Q2

• Target: Q2 Cash flow positive

2021

• Increased partners

• Receipt of multiple milestone

payments

• Diversify to consumer goods

partners potentially

2022

magicmedindustries.com12

For over 25 years the MagicMed team has been discovering building blocks and patenting new

molecular derivatives in the fields of opiates, cannabinoids, and ephedra. Now the team has turned its

extensive expertise to the psychedelics market.

Leadership

Dr. Joseph Tucker is a seasoned executive

who has built several publicly traded

biotechnology companies. He has worked

closely with the MagicMed Science team

since 2013. As CEO of MagicMed Industries,

Dr. Tucker focuses on partnership

development, capital raising and the pursuit

of a successful exit strategy.

Dr. Joseph TuckerCEO

Dr. Jillian HagelCOO

Dr. Jillian Hagel has previously held

COO and Vice President roles in the

biotechnology industry. She focuses

on Science team coordination and

patent filings. Dr. Hagel will lead the

Science team’s laser focus on

delivering partner milestones.

Dr. Peter Facchini has previously held the Chief

Scientific Officer role at other publicly-traded and

private biotechnology companies. A recognized

leader in the development of new molecular

derivatives, Dr. Facchini has published more than

160 scientific papers and holds 20 patents in the

field. At MagicMed Industries Dr. Facchini is

applying his focus to the creation and patenting

of psychedelics-derivatives.

Dr. Peter FacchiniCSO

magicmedindustries.com13

Shares Outstanding: 20.1 million

Warrants*: 13.7 million

Options**: 0

Fully Diluted: 33.8 million

Total funds raised to date: $2.2 million

Total Number of Shareholders: 186

Current Implied Valuation: $5 million

Corporate Structure

* 5 year warrants at $0.25 strike price held by management, scientists and

strategic investors only. No further warrants to be issued until after a

go-public transaction.

** Options to be issued to management and board only after a go-public

transaction.

magicmedindustries.com14

T h a n k Y o u

magicmedindustries.com

For more information please contact:

Dr. Joseph Tucker, PhD

CEO

jtucker@magicmedindustries.com